U.S. Oil and Gas Stock News

Mirion Technologies (NYSE:MIR) is facing material trade policy uncertainty after the US administration imposed new 15% global tariffs under the Trade Act of 1974. The tariffs follow a recent Supreme Court ruling and are being implemented abruptly, affecting companies with international supply chains. For Mirion, the policy shift raises questions around cost structure, operational planning, and future financial results. Mirion Technologies, trading at $21.49, now sits at the center of a...

In February 2026, Select Medical Holdings Corporation reported mixed fourth-quarter and full-year 2025 results, with revenue rising to US$1,396.63 million for the quarter and US$5,452.83 million for the year, while profitability remained under pressure. On the same day, the company declared a US$0.0625 per-share cash dividend and issued 2026 guidance calling for US$5.6 billion to US$5.8 billion in revenue and fully diluted earnings per share of US$1.22 to US$1.32, framing how management sees...

Expro Group Holdings (NYSE:XPRO) has authorized a new $100 million share repurchase program. The company has secured a major multi-year contract in North Africa with an initial four-year term. Recent earnings included higher margins and free cash flow, alongside softer revenue in certain regions. Expro Group, a global energy services provider listed on the NYSE as XPRO, is active across well construction, well flow management, and subsea services. The mix of a sizable buyback authorization...

Corcept Therapeutics FY 2025 earnings snapshot Corcept Therapeutics (CORT) has wrapped up FY 2025 with Q4 revenue of US$202.1 million and basic EPS of US$0.24, alongside net income of US$25.4 million. Over the past six quarters, the company has seen revenue move from US$181.9 million in Q4 2024 to a range between US$157.2 million and US$207.6 million per quarter, while basic EPS has ranged between US$0.19 and US$0.45. With a trailing 12 month net profit margin of 13.1% compared to 20.7% a...

McDonald's (MCD) closed out FY 2025 with fourth quarter revenue of US$7.0 billion and basic EPS of US$3.03, alongside net income of US$2,164 million, setting the tone for a year where trailing 12 month revenue reached US$26.9 billion and EPS came in at US$12.00. Over the past few quarters, revenue has moved from US$5,956 million in Q1 2025 to US$7,078 million in Q3 2025 before landing at US$7,009 million in Q4. Quarterly EPS ranged between US$2.61 and just over US$3.19, with a trailing net...

Trinity Capital (TRIN) closed out FY 2025 with Q4 total revenue of US$77.6 million and basic EPS of US$0.51, alongside trailing twelve month revenue of US$279.5 million and EPS of US$1.96, set against reported earnings growth of 17.3% over the past year. Over recent periods the company has seen revenue move from US$205.2 million on a trailing basis in Q3 2024 to US$226.7 million in Q4 2024 and then to US$279.5 million by Q4 2025. Trailing EPS shifted from US$1.79 to US$2.19 and then to...

Gulfport Energy (GPOR) has wrapped up FY 2025 with fourth quarter revenue of US$355.5 million and basic EPS of US$6.90, alongside net income excluding extra items of US$132.4 million. Over the past year, revenue on a trailing 12 month basis has moved from US$909.2 million in Q4 2024 to US$1.3 billion in Q4 2025, while basic EPS over the same window shifted from a loss of US$14.72 to a profit of US$21.74. This sets up a year in which margins and cash generation are front and center for...

United Therapeutics (UTHR) FY 2025 Earnings Snapshot United Therapeutics (UTHR) closed FY 2025 with fourth quarter revenue of US$790.2 million and basic EPS of US$8.41, capping a twelve month run where trailing revenue reached US$3.2 billion and EPS came in at US$30.13. Over that period, revenue has moved from US$2.9 billion to US$3.2 billion and EPS has shifted from US$26.44 to US$30.13, giving investors a clear view of how the top line and EPS have tracked together. With a net income of...

Pebblebrook Hotel Trust (NYSE:PEB) recently completed a $450 million senior unsecured term loan. The company used part of the proceeds to repay certain mortgages and address near term debt maturities. Management also restored full capacity on its revolving credit facility, increasing available liquidity. Pebblebrook Hotel Trust, trading at $12.24, has had mixed share performance, with a 6.0% return year to date and a 4.6% return over the past year, but weaker 3 year and 5 year returns of...

If you are wondering whether Perfect's current share price reflects its true worth, this breakdown will help you connect the recent market action to what the numbers actually say about value. Perfect's share price closed at US$1.38, with returns of a 5.5% decline over 7 days, a 17.4% decline over 30 days, a 20.2% decline year to date, a 27.7% decline over 1 year and 81.9% and 86.1% declines over 3 and 5 years. This performance sits against a backdrop of ongoing market attention on software...

Matador Resources (MTDR) has wrapped up FY 2025 with fourth quarter revenue of US$848 million and basic EPS of US$1.55, alongside net income excluding extra items of US$192.5 million. This gives investors a clear read on its latest run rate. Over the past year, total revenue on a trailing twelve month basis has moved from US$3.24 billion in Q4 2024 to US$3.70 billion in Q4 2025, while trailing basic EPS shifted from US$7.16 to US$6.10, framing the current quarter against a fuller year of...

ONEOK (NYSE:OKE) reported double digit net income and adjusted EBITDA growth for 2025. The company exceeded synergy targets from recent acquisitions, including Magellan, and retired a significant amount of long term debt. ONEOK raised its quarterly dividend by 4% and continued integrating acquired assets through 2025. Management outlined plans for 2026 that include expansion into fee based earnings and energy solutions for data centers. ONEOK is a large midstream operator focused on natural...

Circle Internet Group (CRCL) just posted its FY 2025 Q4 numbers, with revenue of US$770.2 million and basic EPS of US$0.56, against a trailing twelve month revenue base of US$2.7 billion and basic EPS of US$0.44 loss. The company has seen quarterly revenue move from US$435.4 million in Q4 2024 to US$770.2 million in Q4 2025. Basic EPS shifted from US$0.08 in Q4 2024 through a volatile FY 2025 that included a US$4.48 loss in Q2 before settling at US$0.56 in Q4. This sets the stage for...

If you are wondering whether Advance Auto Parts shares are now a bargain or still a value trap, this article walks through what the current price is really telling you. The stock recently closed at US$50.44, after a 9.8% decline over the last 7 days, a 6.1% gain over 30 days, a 29.7% gain year to date, a 36.9% gain over 1 year, but with 3 year and 5 year returns of 61.1% and 65.8% declines respectively. These moves sit against a backdrop of ongoing attention on the company’s turnaround...

Hovnanian Enterprises (HOV) opened its 2026 financial year with Q1 revenue of US$632 million and basic EPS of US$2.80, setting a measured tone after a volatile run of quarterly results. The company has seen quarterly revenue move from US$674 million and EPS of US$3.88 in Q1 2025 through periods of both profit and loss, including revenue of US$818 million with a loss per share of US$0.60 in Q4 2025. This puts today’s figures in the middle of a choppy trend that keeps the spotlight firmly on...

Kiniksa Pharmaceuticals International (KNSA) closed FY 2025 with Q4 revenue of US$202.1 million and basic EPS of US$0.19, alongside net income of US$14.2 million. On a trailing twelve month basis, revenue was US$677.6 million with basic EPS of US$0.80 and net income of US$59.0 million. The company’s quarterly revenue moved from US$122.5 million and a basic EPS loss of US$0.12 in Q4 2024 to US$202.1 million and basic EPS of US$0.19 in Q4 2025. Over the same period, trailing twelve month net...

Primoris Services (PRIM) has wrapped up FY 2025 with Q4 revenue of US$1.9b and basic EPS of US$0.96, while trailing twelve month revenue reached about US$7.6b and EPS came in at US$5.09 as earnings grew 52% over the past year. The company has seen revenue move from US$6.4b to US$7.6b and trailing net income rise from US$180.9m to US$274.9m over the last year, presenting a picture of expanding profits and firmer margins across the construction and infrastructure work it delivers. See our full...

What Avidity Biosciences’ Recent Returns Signal for Investors Avidity Biosciences (RNA) has drawn attention after a 1 day return close to flat, modest moves over the past week and month, and a very large total return over the past year. For investors, those figures sit alongside a revenue base of US$18.755 million and a reported net loss of US$684.631 million. This highlights that the company remains firmly in a development focused phase. See our latest analysis for Avidity Biosciences. With...

Day One Biopharmaceuticals (DAWN) just reported its FY 2025 numbers, with Q4 total revenue of US$53.7 million and a net loss of US$21.3 million, setting the tone for how investors will read the year as a whole. The company has seen quarterly revenue move from US$29.2 million in Q4 2024 to US$53.7 million in Q4 2025, while Basic EPS shifted from a loss of US$0.64 per share in Q4 2024 to a loss of US$0.19 per share in Q3 2025, giving investors a clear view of how top line scale and loss levels...

Setting the scene on ACV Auctions ACV Auctions (ACVA) has drawn investor attention after a prolonged share price slump, with the stock showing negative returns over the past month, past 3 months, and year to date. At a last close of US$4.51, the wholesale digital auction platform sits against a backdrop of reported annual revenue of US$759.6 million and a net loss of US$66.1 million. This raises questions about how the business fundamentals compare with recent market sentiment. See our latest...

Universal Insurance Holdings FY 2025 Earnings Snapshot Universal Insurance Holdings (UVE) has wrapped up FY 2025 with fourth quarter total revenue of US$407.9 million and basic EPS of US$2.40, alongside net income of US$66.6 million as investors weigh these results against a year where net profit margin moved from 3.9% to 11.4% and earnings growth was very large at about 210.5% year over year. Over recent periods the company has seen total revenue shift from US$384.8 million and basic EPS of...

CeriBell (CBLL) has just closed out FY 2025 with Q4 revenue of US$24.8 million and a basic EPS loss of US$0.36, while trailing 12 month revenue reached US$89.1 million and basic EPS over that period sat at a loss of US$1.46. The company has seen quarterly revenue move from US$18.5 million in Q4 2024 to US$24.8 million in Q4 2025, with basic EPS losses over those quarters ranging between US$0.36 and US$0.40, and trailing 12 month net income remaining in loss territory at US$53.4 million for...

Ironwood Pharmaceuticals (IRWD) just closed out FY 2025 with a mixed Q4 print, reporting revenue of US$47.7 million and a small net loss of US$2.3 million, which translated into EPS of US$0.15 for the trailing twelve months. The company has seen revenue move from US$351.4 million on a trailing basis in Q4 2024 to US$296.2 million in Q4 2025, while trailing EPS shifted from roughly flat at US$0.01 to US$0.15. This sets up a picture in which margins have recently firmed even as top line...

Supernus Pharmaceuticals FY 2025 Earnings Snapshot Supernus Pharmaceuticals (SUPN) has wrapped up FY 2025 with fourth quarter revenue of US$211.6 million, Basic EPS of a US$0.07 loss, and net income excluding extra items showing a US$4.1 million loss. The company reported an increase in revenue from US$174.2 million in Q4 2024 to US$211.6 million in Q4 2025, while Basic EPS moved from US$0.28 in Q4 2024 to a US$0.07 loss in Q4 2025. This combination highlights an expanding top line alongside...